JAGUAR Trial (Outside United States; OUS): ObJective Analysis to GaUge EVAR Outcomes Through Randomization
Reason given: This is an EU protocol, and as a company, it was decided to only enroll within the US so this protocol/study is being withdrawn.
Trial details
- Who runs it
- Endologix
- Trial code
- NCT05409118
- Record updated
- 7 August 2025
- Original description
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints.Read full original descriptionShow less
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints.
Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Inclusion: Adult age 21 and older; Subjects with minimum of 2 year life expectancy; Subjects have signed the informed consent document; Subjects with unruptured infrarenal AAA who are assessed by the Investigator to be eligible for endovascular Abdominal Aortic Aneurysm Repair with the trial devices; Patient must be able and willing to comply with all required follow-up exams.
Exclusion: Subjects with pre-existing EVAR, i.e., in need of repair/intervention of a previously failed EVAR; Patient has other medical, social, or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations; Known allergy to any of the device components; Known connective tissue disorders; Known active infection; Currently participating in another trial where the primary endpoint has not been reached yet; Pregnant (females of childbearing potential only).